|
🐜
|
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
21 auth.
A. Zhu,
R. Finn,
J. Edeline,
S. Cattan,
S. Ogasawara,
D. Palmer,
C. Verslype,
V. Zagonel,
L. Fartoux,
A. Vogel,
...
D. Sarker,
G. Verset,
S. Chan,
J. Knox,
B. Daniele,
A. Webber,
S. Ebbinghaus,
Junshui Ma,
A. Siegel,
A. Cheng,
M. Kudo
|
10 |
2018 |
10
🐜
|
|
🐜
|
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
21 auth.
M. Omata,
A. Cheng,
N. Kokudo,
M. Kudo,
J. Lee,
J. Jia,
R. Tateishi,
K. Han,
Y. K. Chawla,
S. Shiina,
...
W. Jafri,
D. Payawal,
Takamasa Ohki,
S. Ogasawara,
Pei‐Jer Chen,
C. Lesmana,
L. Lesmana,
R. Gani,
S. Obi,
A. Dokmeci,
S. Sarin
|
10 |
2017 |
10
🐜
|
|
🐜
|
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
20 auth.
R. Finn,
B. Ryoo,
P. Merle,
M. Kudo,
M. Bouattour,
Ho Yeong Lim,
V. Breder,
J. Edeline,
Y. Chao,
S. Ogasawara,
...
T. Yau,
M. Garrido,
S. Chan,
J. Knox,
B. Daniele,
S. Ebbinghaus,
E. Chen,
A. Siegel,
A. Zhu,
A. Cheng
|
10 |
2019 |
10
🐜
|
|
🐜
|
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
16 auth.
M. Kudo,
O. Matsui,
N. Izumi,
H. Iijima,
M. Kadoya,
Y. Imai,
T. Okusaka,
S. Miyayama,
K. Tsuchiya,
K. Ueshima,
...
A. Hiraoka,
M. Ikeda,
S. Ogasawara,
T. Yamashita,
T. Minami,
K. Yamakado
|
9 |
2014 |
9
🐜
|
|
🐜
|
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
25 auth.
M. Kudo,
Y. Kawamura,
K. Hasegawa,
R. Tateishi,
K. Kariyama,
S. Shiina,
H. Toyoda,
Y. Imai,
A. Hiraoka,
M. Ikeda,
N. Izumi,
M. Moriguchi,
S. Ogasawara,
Y. Minami,
K. Ueshima,
...
T. Murakami,
S. Miyayama,
O. Nakashima,
H. Yano,
M. Sakamoto,
E. Hatano,
M. Shimada,
N. Kokudo,
S. Mochida,
T. Takehara
|
8 |
2021 |
8
🐜
|
|
🐜
|
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
14 auth.
M. Kudo,
O. Matsui,
N. Izumi,
M. Kadoya,
T. Okusaka,
S. Miyayama,
K. Yamakado,
K. Tsuchiya,
K. Ueshima,
A. Hiraoka,
...
M. Ikeda,
S. Ogasawara,
T. Yamashita,
T. Minami
|
7 |
2014 |
7
🐜
|
|
🐜
|
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
22 auth.
M. Kudo,
K. Ueshima,
O. Yokosuka,
S. Ogasawara,
S. Obi,
N. Izumi,
H. Aikata,
H. Nagano,
E. Hatano,
Y. Sasaki,
...
K. Hino,
T. Kumada,
Kazuhide Yamamoto,
Y. Imai,
S. Iwadou,
C. Ogawa,
T. Okusaka,
F. Kanai,
K. Akazawa,
K. Yoshimura,
P. Johnson,
Y. Arai
|
7 |
2018 |
7
🐜
|
|
🐜
|
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
20 auth.
R. Finn,
B. Ryoo,
P. Merle,
M. Kudo,
M. Bouattour,
Ho Yeong Lim,
V. Breder,
J. Edeline,
Y. Chao,
S. Ogasawara,
...
T. Yau,
M. Garrido,
S. Chan,
J. Knox,
B. Daniele,
S. Ebbinghaus,
E. Chen,
A. Siegel,
A. Zhu,
A. Cheng
|
7 |
2019 |
7
🐜
|
|
🦁
|
Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization
10 auth.
S. Ogasawara,
T. Chiba,
Y. Ooka,
Naoya Kanogawa,
T. Motoyama,
E. Suzuki,
...
A. Tawada,
F. Kanai,
M. Yoshikawa,
O. Yokosuka
|
7 |
2014 |
7
🦁
|
|
🐢
|
Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment
F. Piscaglia,
S. Ogasawara
|
6 |
2018 |
6
🐢
|
|
🐜
|
Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma
15 auth.
T. Chiba,
Tomoko Saito,
Kaori Yuki,
Y. Zen,
S. Koide,
Naoya Kanogawa,
T. Motoyama,
S. Ogasawara,
E. Suzuki,
Y. Ooka,
...
A. Tawada,
M. Otsuka,
M. Miyazaki,
A. Iwama,
O. Yokosuka
|
6 |
2015 |
6
🐜
|
|
🐜
|
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
22 auth.
K. Ueshima,
S. Ogasawara,
M. Ikeda,
Y. Yasui,
T. Terashima,
T. Yamashita,
S. Obi,
Shin'pei Sato,
H. Aikata,
T. Ohmura,
...
Hidekatsu Kuroda,
Takamasa Ohki,
K. Nagashima,
Y. Ooka,
M. Takita,
M. Kurosaki,
K. Chayama,
S. Kaneko,
N. Izumi,
N. Kato,
M. Kudo,
M. Omata
|
6 |
2020 |
6
🐜
|
